Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite sublingual film is an allergen immunotherapy (AIT) candidate developed by Zhejiang Wolwo Bio-Pharmaceutical for the treatment of allergic rhinitis, allergic conjunctivitis, and asthma triggered by house dust mites. The product consists of a sublingual film formulation containing standardized extracts of house dust mite allergens (typically *Dermatophagoides farinae*). By delivering the allergen to the sublingual mucosa, the film aims to induce peripheral T-cell tolerance, increase the production of regulatory T cells (Tregs), and shift the immune response from a Th2-biased (allergic) profile to a Th1-biased or regulatory profile. This formulation is intended to provide a more convenient and precise dosing alternative to traditional sublingual drops.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite sublingual film.